AIXSCAN, INC. ARC60 Started Imaging Patients In The U.S.

AIxSCAN, Inc. began U.S. clinical trials in 2023 with plans to file for 510k submission in 2024.

SUNNYVALE, Calif.--(BUSINESS WIRE)--AIxSCAN, Inc. began clinical trials in late 2023. The AIxSCAN, Inc. team is very pleased with the early ARC60 imaging results, both in terms of depiction of details and consistency of imaging quality.

AIxSCAN, Inc. received additional seed funding in early September 2023 to support clinical trials and engineering projects.

UC San Diego Health is the first site for the clinical trials to be conducted.

Between late 2023 and early 2024, AIxSCAN, Inc. plans to produce over 50 lung disease patients scans in the U.S. and up to 1,000 total lung disease patients scans within 2 years. AIxSCAN, Inc. will use some of the data to support its 510k submission to the FDA in 2024.

AIxSCAN, Inc. is also in final discussions to partner with three more institutions as soon as additional ARC60 units come out of production.

Finally, Norbert Pelc, Sc.D., Professor of Radiology, Emeritus at Stanford University and AIxSCAN, Inc. Advisory Board member, is also very impressed with the ARC60 imaging platform capabilities. He said:

This innovative technology has the potential to change the way we diagnose a range of medical conditions. The AIxSCAN tomosynthesis X-ray scanner does not completely avoid the superimposition limitations of radiography, but the early results from the prototype system are very encouraging and suggest the technology can play a significant role. I believe that AIxSCAN's tomosynthesis X-ray scanner has a very good chance of becoming a valuable tool for the medical community. This technology has the potential to improve patient care and save lives.

For more information, visit www.aixscan.com.

ABOUT THE COMPANY

AIxSCAN, Inc. is introducing the next generation tomosynthesis X-ray imaging system, which combines the functionalities of digital radiography (DR), computerized tomography (CT), and an experienced radiologist into a single package.

This patent-protected, direct AI-based medical X-ray imaging system is a paradigm-shift from conventional digital radiography (DR) and computed tomography (CT), aimed to enable accurate diagnoses and tracking of abnormalities over time. With this system’s technology, we aim to complete a scan, assist the physician in providing a diagnosis, and create a report efficiently and at a low radiation dose (from 1/20 to 1/40 that of typical CT).

Contacts

JQ Liu
President
jliu@aixscan.com

JC Firer
VP, Business Development
jcfirer@aixscan.com
(925) 519-6655